Event Details
October 01, 2017
Description
FDA accepted GW Pharmaceuticals’ New Drug Application (NDA) for the cannabis-derived drug Epidiolex.
Participants (2)
| Name | Type | Mentions | |
|---|---|---|---|
| FDA | person | 0 | View Entity |
| ICA | organization | 1597 | View Entity |
Source Documents (1)
HOUSE_OVERSIGHT_024722.jpg
This document is page 86 of a December 2017 Cannabis Investment Report by Ackrell Capital. It discusses the regulatory landscape involving the DEA and FDA, specifically highlighting GW Pharmaceuticals' NDA for Epidiolex and providing six predictions regarding the path to federal cannabis legalization in the US. The document bears a 'HOUSE_OVERSIGHT' Bates stamp, indicating it was likely part of a document production for a congressional investigation.
Related Events
Events with shared participants
FDA convened a meeting to analyze data on the drug Praluent, leading to its approval for a larger group of patients than expected.
Date unknown • U.S.
The FDA clearing the drug Praluent for patients with heterozygous familial hypercholesterolemia and certain types of heart disease.
Date unknown
Acquisition of Interlace Medical by Hologix
Date unknown • N/A
FDA approval of Marinol and Cesamet
1985-01-01 • USA
Marinol approved for treatment of anorexia associated with AIDS
1992-01-01 • USA
Syndros approved by the FDA
2016-01-01 • USA
Mexican government released list of 38 approved OTC cannabis products
2018-11-01 • Mexico
Projected legalization of cannabis for adult-use purposes
2019-01-01 • Mexico
Supreme Court decision regarding the broadcasting of Carlin's routine on Pacifica radio.
Date unknown • USA
Arizona Republican Party enacts a resolution declaring the US a 'Christian Nation'.
Date unknown • Arizona
Discussion 0
No comments yet
Be the first to share your thoughts on this epstein event